Pretreated
Case report
NSCLC
Osimertinib
Resistance
Targeted therapy
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
13
02
2023
revised:
14
06
2023
accepted:
24
06
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated
Identifiants
pubmed: 37533438
doi: 10.1016/j.jtocrr.2023.100545
pii: S2666-3643(23)00088-7
pmc: PMC10392131
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100545Informations de copyright
© 2023 The Authors.
Références
Cancer Treat Rev. 2017 Feb;53:128-137
pubmed: 28110254
J Thorac Oncol. 2019 May;14(5):802-815
pubmed: 30831205
NPJ Precis Oncol. 2021 Feb 12;5(1):5
pubmed: 33580193
J Clin Oncol. 2020 Feb 20;38(6):538-547
pubmed: 31809241
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261